Close Menu

NEW YORK – South San Francisco-based Veracyte and MaviDx said on Wednesday they have signed an agreement for MaviDx to develop ultra-high throughput genomic testing for SARS-CoV-2 on Veracyte's nCounter diagnostic platform.

As part of the collaboration, Miami-based MaviDx will develop, validate, secure regulatory approvals for, and commercialize SARS-CoV-2 and other infectious disease tests, including for influenza, on the nCounter system.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Pfizer and BioNTech announce they are seeking FDA authorization for their candidate SARS-CoV-2 vaccine.

Science has retracted a 2007 paper from a former Dutch minister and his colleagues, according to Retraction Watch.

The New York Times reports that a plan to cull minks in Denmark to prevent the spread of a new SARS-CoV-2 strain led to calls for the prime minister's resignation.

In Science this week: winner of the Science & SciLifeLab Prize for Young Scientists, and more.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.